241 results
Page 2 of 13
DEFA14A
EX-3.1
8nrm o6osi
14 Mar 24
Additional proxy soliciting materials
6:10am
DEFA14A
EX-2.1
nvjw0ck0k9
14 Mar 24
Additional proxy soliciting materials
6:10am
DEFA14A
2qvk2f163njynb0l0r
14 Mar 24
Additional proxy soliciting materials
6:10am
DEFA14A
EX-10.1
ox72zct
14 Mar 24
Additional proxy soliciting materials
6:10am
8-K
EX-3.1
rkfhhn8fxc82qjhd1 bj
14 Mar 24
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease
6:09am
8-K
EX-2.1
qha2 salzjkgvr
14 Mar 24
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease
6:09am
8-K
EX-10.1
9mzcjk007f
14 Mar 24
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease
6:09am
8-K
jgzar1nmnxy ymbe
14 Mar 24
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease
6:09am
8-K
EX-4.1
crrr1v
5 Mar 24
First Wave BioPharma, Inc. to raise approximately $4.0 million of Gross Proceeds in Registered Direct Offering
5:26pm
8-K
EX-10.2
va3 jsxna
5 Mar 24
First Wave BioPharma, Inc. to raise approximately $4.0 million of Gross Proceeds in Registered Direct Offering
5:26pm
8-K
EX-4.2
6zdjprg 4yih
5 Mar 24
First Wave BioPharma, Inc. to raise approximately $4.0 million of Gross Proceeds in Registered Direct Offering
5:26pm
424B5
mlhjudiflgumuylg6oap
4 Mar 24
Prospectus supplement for primary offering
5:29pm
424B3
woughc
18 Jan 24
Prospectus supplement
4:01pm
8-K
EX-4.1
jl84kpzh
27 Dec 23
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
5:23pm
8-K
EX-10.1
81qorl 9l
27 Dec 23
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
5:23pm
8-K
phqoj6hjzylgqtgyo
18 Dec 23
Other Events
7:00am